Skip to main content
Top
Published in: Drug Safety 8/2015

01-08-2015 | Original Research Article

A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance

Authors: Yihua Xu, Xiaofeng Zhou, Brandon T. Suehs, Abraham G. Hartzema, Michael G. Kahn, Yola Moride, Brian C. Sauer, Qing Liu, Keran Moll, Margaret K. Pasquale, Vinit P. Nair, Andrew Bate

Published in: Drug Safety | Issue 8/2015

Login to get access

Abstract

Introduction

An often key component to coordinating surveillance activities across distributed networks is the design and implementation of a common data model (CDM). The purpose of this study was to evaluate two drug safety surveillance CDMs from an ecosystem perspective to better understand how differences in CDMs and analytic tools affect usability and interpretation of results.

Methods

Humana claims data from 2007 to 2012 were mapped to Observational Medical Outcomes Partnership (OMOP) and Mini-Sentinel CDMs. Data were described and compared at the patient level by source code and mapped concepts. Study cohort construction and effect estimates were also compared using two different analytical methods—one based on a new user design implementing a high-dimensional propensity score (HDPS) algorithm and the other based on univariate self-controlled case series (SCCS) design—across six established positive drug-outcome pairs to learn how differences in CDMs and analytics influence steps in the database analytic process and results.

Results

Claims data for approximately 7.7 million Humana health plan members were transformed into the two CDMs. Three health outcome cohorts and two drug cohorts showed differences in cohort size and constituency between Mini-Sentinel and OMOP CDMs, which was a result of multiple factors. Overall, the implementation of the HDPS procedure on Mini-Sentinel CDM detected more known positive associations than that on OMOP CDM. The SCCS method results were comparable on both CDMs. Differences in the implementation of the HDPS procedure between the two CDMs were identified; analytic model and risk period specification had a significant impact on the performance of the HDPS procedure on OMOP CDM.

Conclusions

Differences were observed between OMOP and Mini-Sentinel CDMs. The analysis of both CDMs at the data model level indicated that such conceptual differences had only a slight but not significant impact on identifying known safety associations. Our results show that differences at the ecosystem level of analyses across the CDMs can lead to strikingly different risk estimations, but this can be primarily attributed to the choices of analytic approach and their implementation in the community-developed analytic tools. The opportunities of using CDMs are clear, but our study shows the need for judicious comparison of analyses across the CDMs. Our work emphasizes the need for ongoing efforts to ensure sustainable transparent platforms to maintain and develop CDMs and associated tools for effective safety surveillance.
Appendix
Available only for authorised users
Footnotes
1
MedDRA® terminology is the international medical terminology developed under the auspices of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). MedDRA® trademark is owned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on behalf of ICH.
 
Literature
1.
2.
3.
go back to reference Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;48(6 Suppl):S45–51. doi:10.1097/MLR.0b013e3181d9919f.PubMedCrossRef Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;48(6 Suppl):S45–51. doi:10.​1097/​MLR.​0b013e3181d9919f​.PubMedCrossRef
4.
go back to reference Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600–6.PubMedCrossRef Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600–6.PubMedCrossRef
5.
go back to reference Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(S1):23–31.PubMedCrossRef Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(S1):23–31.PubMedCrossRef
8.
go back to reference Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15. doi:10.1002/sim.5620.PubMedCrossRef Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401–15. doi:10.​1002/​sim.​5620.PubMedCrossRef
11.
go back to reference Toh S, Avorn J, D’Agostino RB, Gurwitz JH, Psaty BM, Rothman KJ, et al. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf. 2013;22(10):1036–45.PubMed Toh S, Avorn J, D’Agostino RB, Gurwitz JH, Psaty BM, Rothman KJ, et al. Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf. 2013;22(10):1036–45.PubMed
13.
go back to reference Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36(2):119–34.PubMedCrossRef Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Saf. 2013;36(2):119–34.PubMedCrossRef
14.
go back to reference Coloma P, Avillach P, Salvo F, Schuemie M, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13–23. doi:10.1007/s40264-012-0002-x.PubMedCrossRef Coloma P, Avillach P, Salvo F, Schuemie M, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36(1):13–23. doi:10.​1007/​s40264-012-0002-x.PubMedCrossRef
15.
go back to reference Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(1):33–47.CrossRef Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(1):33–47.CrossRef
16.
go back to reference Schneider G, Kachroo S, Jones N, Crean S, Rotella P, Avetisyan R, et al. A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(S1):240–7.PubMedCrossRef Schneider G, Kachroo S, Jones N, Crean S, Rotella P, Avetisyan R, et al. A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(S1):240–7.PubMedCrossRef
17.
go back to reference Lo Re V, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration’s Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22(8):861–72.PubMedCentralPubMedCrossRef Lo Re V, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, et al. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration’s Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013;22(8):861–72.PubMedCentralPubMedCrossRef
18.
19.
go back to reference Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512–22.PubMedCentralPubMedCrossRef Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512–22.PubMedCentralPubMedCrossRef
21.
go back to reference Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res. 2009;18(1):7–26.PubMedCrossRef Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res. 2009;18(1):7–26.PubMedCrossRef
23.
go back to reference Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23(2):238.PubMedCentralPubMedCrossRef Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23(2):238.PubMedCentralPubMedCrossRef
24.
go back to reference Reich CG, Ryan PB, Suchard MA. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S195–204.PubMedCrossRef Reich CG, Ryan PB, Suchard MA. The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S195–204.PubMedCrossRef
25.
go back to reference Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S59–72. doi:10.1007/s40264-013-0099-6.PubMedCrossRef Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S59–72. doi:10.​1007/​s40264-013-0099-6.PubMedCrossRef
Metadata
Title
A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance
Authors
Yihua Xu
Xiaofeng Zhou
Brandon T. Suehs
Abraham G. Hartzema
Michael G. Kahn
Yola Moride
Brian C. Sauer
Qing Liu
Keran Moll
Margaret K. Pasquale
Vinit P. Nair
Andrew Bate
Publication date
01-08-2015
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2015
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-015-0297-5

Other articles of this Issue 8/2015

Drug Safety 8/2015 Go to the issue